Advances in the prevention, management, and treatment of community-acquired pneumonia

F1000Research

Volumn 5, Issue , 2016, Pages

  Pletz, Mathias W ^a   Rohde, Gernot G ^b   Welte, Tobias ^c   Kolditz, Martin ^d   Ott, Sebastian ^e  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AZITHROMYCIN; BETA LACTAM; C REACTIVE PROTEIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; COPEPTIN; ENDOTHELIN 1; ERYTHROMYCIN; GLUCOSE; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PENICILLIN V; PNEUMOCOCCUS VACCINE; PREDNISOLONE; PROADRENOMEDULLIN; PROCALCITONIN; SIMVASTATIN; TETRACYCLINE DERIVATIVE;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ARTIFICIAL VENTILATION; BACTERIAL MENINGITIS; CARDIOTOXICITY; CAUSE OF DEATH; CHLAMYDIA PNEUMONIAE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DETERIORATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; EMERGENCY WARD; EMPYEMA; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; INTENSIVE CARE; LEUKOCYTE COUNT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; MYCOPLASMA PNEUMONIAE; NONHUMAN; OPEN STUDY; PNEUMONIA SEVERITY INDEX; PRACTICE GUIDELINE; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; RISK FACTOR; RISK REDUCTION; SEPSIS; SEPTIC SHOCK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME; VACCINATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84964645052     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.7657.1     Document Type: Review

References (106)

1. Schnoor M Hedicke J Dalhoff K: Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect. 2007;55(3):233-9. 17599417 10.1016/j.jinf.2007.04.355
2. Ewig S Birkner N Strauss R: New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009;64(12):1062-9. 19454409 10.1136/thx.2008.109785 2782114
3. Jansen AG Rodenburg GD de Greeff SC: Invasive pneumococcal disease in the Netherlands: Syndromes, outcome and potential vaccine benefits. Vaccine. 2009;27(17):2394-401. 19428856 10.1016/j.vaccine.2009.01.127
4. GBD 2013 Mortality and Causes of Death Collaborators: Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. 25530442 10.1016/S0140-6736(14)61682-2 4340604
5. Welte T Torres A Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71-9. 20729232 10.1136/thx.2009.129502
6. Drijkoningen JJ Rohde GG: Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45-51. 24313448 10.1111/1469-0691.12461
7. Pletz MW von Baum H van der Linden M: The burden of pneumococcal pneumonia - experience of the German competence network CAPNETZ. Pneumologie. 2012;66(8):470-5. 22875730 10.1055/s-0032-1310103
8. Bafadhel M Haldar K Barker B: Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int J Chron Obstruct Pulmon Dis. 2015;10(1):1075-83. 26089657 10.2147/COPD.S80091 4468933
9. Braeken D Franssen F Schütte H: Increased Severity and Mortality of CAP in COPD: Results from the German Competence Network, CAPNETZ. J COPD F. 2014;2(2):131-40. 10.15326/jcopdf.2.2.2014.0149
10. Bierbaum S Königsfeld N Besazza N: Performance of a novel microarray multiplex PCR for the detection of 23 respiratory pathogens (SYMP-ARI study). Eur J Clin Microbiol Infect Dis. 2012;31(10):2851-61. 22644053 10.1007/s10096-012-1639-1
11. Bierbaum S Forster J Berner R: Detection of respiratory viruses using a multiplex real-time PCR assay in Germany, 2009/10. Arch Virol. 2014;159(4):669-76. 24126621 10.1007/s00705-013-1876-3
12. von Baum H Schweiger B Welte T: How deadly is seasonal influenza-associated pneumonia? The German Competence Network for Community-Acquired Pneumonia. Eur Respir J. 2011;37(5):1151-7. 20817703 10.1183/09031936.00037410
13. Johansson N Kalin M Tiveljung-Lindell A: Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202-9. 20014950 10.1086/648678
14. von Baum H Welte T Marre R: Mycoplasma pneumoniae pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). BMC Infect Dis. 2009;9:62. 19439072 10.1186/1471-2334-9-62 2689234
15. Dumke R Schnee C Pletz MW: Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerging Infect Dis. 2015;21(3):426-34. 25693633 10.3201/eid2103.140927 4344269
16. von Baum H Ewig S Marre R: Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis. 2008;46(9):1356-64. 18419436 10.1086/586741 F1000 Recommendation
17. Arancibia F Cortes CP Valdés M: Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile. Chest. 2014;145(2):290-6. 23764871 10.1378/chest.13-0162
18. Krüger S Ewig S Papassotiriou J: Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ. Respir Res. 2009;10(1):65. 19594893 10.1186/1465-9921-10-65 2714042
19. Bello S Mincholé E Fandos S: Inflammatory response in mixed viral-bacterial community-acquired pneumonia. BMC Pulm Med. 2014;14:123. 25073709 10.1186/1471-2466-14-123 4118651 F1000 Recommendation
20. Schuetz P Suter-Widmer I Chaudri A: Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37(2):384-92. 20595156 10.1183/09031936.00035610 F1000 Recommendation
21. Krüger S Ewig S Marre R: Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008;31(2):349-55. 17959641 10.1183/09031936.00054507
22. Zhydkov A Christ-Crain M Thomann R: Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin Chem Lab Med. 2015;53(4):559-66. 25014522 10.1515/cclm-2014-0456 F1000 Recommendation
23. Krüger S Ewig S Kunde J: Assessment of inflammatory markers in patients with community-acquired pneumonia--influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta. 2010;411(23-24):1929-34. 20699094 10.1016/j.cca.2010.08.004
24. Le Bel J Hausfater P Chenevier-Gobeaux C: Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. Crit Care. 2015;19:366. 26472401 10.1186/s13054-015-1083-6 4608327 F1000 Recommendation
25. van Vugt SF Broekhuizen BD Lammens C: Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study. BMJ. 2013;346:f2450. 23633005 10.1136/bmj.f2450 3639712 F1000 Recommendation
26. Krüger S Ewig S Giersdorf S: Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010;182(11):1426-34. 20639437 10.1164/rccm.201003-0415OC F1000 Recommendation
27. España PP Capelastegui A Mar C: Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia. J Infect. 2015;70(5):457-66. 25499199 10.1016/j.jinf.2014.12.003 F1000 Recommendation
28. Krüger S Ewig S Giersdorf S: Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in patients with community-acquired pneumonia: results from the german competence network CAPNETZ. Respir Med. 2014;108(11):1696-705. 25306251 10.1016/j.rmed.2014.09.014
29. Lepper PM Ott S Nüesch E: Serum glucose levels for predicting death in patients admitted to hospital for community acquired pneumonia: prospective cohort study. BMJ. 2012;344:e3397. 22645184 10.1136/bmj.e3397 3362658 F1000 Recommendation
30. Kolditz M Höffken G Martus P: Serum cortisol predicts death and critical disease independently of CRB-65 score in community-acquired pneumonia: a prospective observational cohort study. BMC Infect Dis. 2012;12:90. 22501026 10.1186/1471-2334-12-90 3353228 F1000 Recommendation
31. Gamble JM Eurich DT Marrie TJ: Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia. Am J Med. 2010;123(6):556.e11-6. 20569764 10.1016/j.amjmed.2009.11.021 F1000 Recommendation
32. Bauer TT Ewig S Marre R: CRB-65 predicts death from community-acquired pneumonia. J Intern Med. 2006;260(1):93-101. 16789984 10.1111/j.1365-2796.2006.01657.x
33. Ewig S Bauer T Richter K: Prediction of in-hospital death from community-acquired pneumonia by varying CRB-age groups. Eur Respir J. 2013;41(4):917-22. 22903962 10.1183/09031936.00065212 F1000 Recommendation
34. Bauer TT Welte T Strauss R: Why do nonsurvivors from community-acquired pneumonia not receive ventilatory support? Lung. 2013;191(4):417-24. 23645127 10.1007/s00408-013-9467-3
35. Fine MJ Auble TE Yealy DM: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243-50. 8995086 10.1056/NEJM199701233360402
36. Lim WS van der Eerden MM Laing R: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5):377-82. 12728155 10.1136/thorax.58.5.377 1746657
37. Loke YK Kwok CS Niruban A: Value of severity scales in predicting mortality from community-acquired pneumonia: systematic review and meta-analysis. Thorax. 2010;65(10):884-90. 20729235 10.1136/thx.2009.134072
38. Chalmers JD Singanayagam A Akram AR: Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis. Thorax. 2010;65(10):878-83. 20729231 10.1136/thx.2009.133280
39. Kolditz M Ewig S Schütte H: Assessment of oxygenation and comorbidities improves outcome prediction in patients with community-acquired pneumonia with a low CRB-65 score. J Intern Med. 2015;278(2):193-202. 25597400 10.1111/joim.12349
40. Dwyer R Hedlund J Henriques-Normark B: Improvement of CRB-65 as a prognostic tool in adult patients with community-acquired pneumonia. BMJ Open Respir Res. 2014;1(1):e000038. 25478185 10.1136/bmjresp-2014-000038 4212804 F1000 Recommendation
41. Corrales-Medina VF Musher DM Wells GA: Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773-81. 22219349 10.1161/CIRCULATIONAHA.111.040766 F1000 Recommendation
42. Aliberti S Ramirez J Cosentini R: Acute myocardial infarction versus other cardiovascular events in community-acquired pneumonia. ERJ Open Res. 2015;1(1): 00020-2015-20-2015. 10.1183/23120541.00020-2015 F1000 Recommendation
43. El-Solh AA Alhajhusain A Abou Jaoude P: Validity of severity scores in hospitalized patients with nursing home-acquired pneumonia. Chest. 2010;138(6):1371-6. 20507947 10.1378/chest.10-0494 F1000 Recommendation
44. Majumdar SR Eurich DT Gamble JM: Oxygen saturations less than 92% are associated with major adverse events in outpatients with pneumonia: a population-based cohort study. Clin Infect Dis. 2011;52(3):325-31. 21217179 10.1093/cid/ciq076 F1000 Recommendation
45. Choudhury G Chalmers JD Mandal P: Physician judgement is a crucial adjunct to pneumonia severity scores in low-risk patients. Eur Respir J. 2011;38(3):643-8. 21406507 10.1183/09031936.00172910 F1000 Recommendation
46. Dwyer R Hedlund J Darenberg J: Improvement of CRB-65 as a prognostic scoring system in adult patients with bacteraemic pneumococcal pneumonia. Scand J Infect Dis. 2011;43(6-7):448-55. 21370939 10.3109/00365548.2011.562529 F1000 Recommendation
47. Kolditz M Ewig S Klapdor B: Community-acquired pneumonia as medical emergency: predictors of early deterioration. Thorax. 2015;70(6):551-8. 25782758 10.1136/thoraxjnl-2014-206744
48. Aliberti S Amir A Peyrani P: Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia. Chest. 2008;134(5):955-62. 18583514 10.1378/chest.08-0334
49. Aliberti S Brambilla AM Chalmers JD: Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. Respir Res. 2014;15(1):27. 24593040 10.1186/1465-9921-15-27 4015148 F1000 Recommendation
50. Dremsizov T Clermont G Kellum JA: Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest. 2006;129(4):968-78. 16608946 10.1378/chest.129.4.968
51. Phua J Ngerng WJ Lim TK: The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J. 2010;36(4):826-33. 20185424 10.1183/09031936.00154209
52. Ewig S Torres A: Community-acquired pneumonia as an emergency: time for an aggressive intervention to lower mortality. Eur Respir J. 2011;38(2):253-60. 21349916 10.1183/09031936.00199810
53. Kolditz M Ewig S Höffken G: Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J. 2013;41(4):974-84. 23018905 10.1183/09031936.00104412
54. Chalmers JD Mandal P Singanayagam A: Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis. Intensive Care Med. 2011;37(9):1409-20. 21660535 10.1007/s00134-011-2261-x F1000 Recommendation
55. Chalmers JD Taylor JK Mandal P: Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care. Clin Infect Dis. 2011;53(6):503-11. 21865188 10.1093/cid/cir463 F1000 Recommendation
56. Salih W Schembri S Chalmers JD: Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data. Eur Respir J. 2014;43(3):842-51. 24114960 10.1183/09031936.00089513 F1000 Recommendation
57. Lim HF Phua J Mukhopadhyay A: IDSA/ATS minor criteria aid pre-intensive care unit resuscitation in severe community-acquired pneumonia. Eur Respir J. 2014;43(3):852-62. 24176994 10.1183/09031936.00081713 F1000 Recommendation
58. Ott SR Hauptmeier BM Ernen C: Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis. Eur Respir J. 2012;39(3):611-8. 21965229 10.1183/09031936.00098411
59. Confalonieri M Urbino R Potena A: Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171(3):242-8. 15557131 10.1164/rccm.200406-808OC F1000 Recommendation
60. Snijders D Daniels JM de Graaff CS: Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181(9):975-82. 20133929 10.1164/rccm.200905-0808OC F1000 Recommendation
61. Fernández-Serrano S Dorca J Garcia-Vidal C: Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15(2):R96. 21406101 10.1186/cc10103 3219361
62. Meijvis SC Hardeman H Remmelts HH: Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9782):2023-30. 21636122 10.1016/S0140-6736(11)60607-7 F1000 Recommendation
63. Blum CA Nigro N Briel M: Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385(9977):1511-8. 25608756 10.1016/S0140-6736(14)62447-8 F1000 Recommendation
64. Torres A Sibila O Ferrer M: Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313(7):677-86. 25688779 10.1001/jama.2015.88 F1000 Recommendation
65. Wan YD Sun TW Liu ZQ: Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Chest. 2016;149(1):209-19. 26501852 10.1378/chest.15-1733 F1000 Recommendation
66. ADRENAL trial. ClinicalTrials.gov. NCT01448109. Reference Source
67. ESCAPe trial. ClinicalTrials.gov. NCT01283009. Reference Source
68. Rodrigo C Leonardi-Bee J Nguyen-Van-Tam JS: Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis. 2015;212(2):183-94. 25406333 10.1093/infdis/jiu645 F1000 Recommendation
69. Myles P Nguyen-Van-Tam JS Semple MG: Differences between asthmatics and nonasthmatics hospitalised with influenza A infection. Eur Respir J. 2013;41(4):824-31. 22903963 10.1183/09031936.00015512 3612580 F1000 Recommendation
70. Viasus D Garcia-Vidal C Gudiol F: Statins for community-acquired pneumonia: current state of the science. Eur J Clin Microbiol Infect Dis. 2010;29(2):143-52. 19943074 10.1007/s10096-009-0835-0
71. Chalmers JD Short PM Mandal P: Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med. 2010;104(8):1081-91. 20447815 10.1016/j.rmed.2010.04.005
72. Schlienger RG Fedson DS Jick SS: Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy. 2007;27(3):325-32. 17316144 10.1592/phco.27.3.325
73. Myles PR Hubbard RB McKeever TM: Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2009;18(4):269-75. 19235776 10.1002/pds.1715
74. Vinogradova Y Coupland C Hippisley-Cox J: Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract. 2011;61(592):e742-8. 22054338 10.3399/bjgp11X606654 3207092
75. Dublin S Jackson ML Nelson JC: Statin use and risk of community acquired pneumonia in older people: population based case-control study. BMJ. 2009;338:b2137. 19531550 10.1136/bmj.b2137 2697311
76. Fleming DM Verlander NQ Elliot AJ: An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. Epidemiol Infect. 2010;138(9):1281-8. 20109259 10.1017/S0950268810000105
77. Viasus D Garcia-Vidal C Simonetti AF: The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ Open. 2015;5(1):e006251. 25564143 10.1136/bmjopen-2014-006251 4289727 F1000 Recommendation
78. Papazian L Roch A Charles PE: Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA. 2013;310(16):1692-700. 24108510 10.1001/jama.2013.280031 F1000 Recommendation
79. Höffken G Lorenz J Kern W: Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia. Pneumologie. 2010;64(3):149-54. 20180179 10.1055/s-0029-1243910
80. Woodhead M Blasi F Ewig S: Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect. 2011;17(Suppl 6):E1-59. 21951385 10.1111/j.1469-0691.2011.03672.x
81. Creutz P Kothe H Braun M: Failure of Ambulatory Treatment in Cap Patients Leading to Subsequent Hospitalization and its Association to Risk Factors. J Pulmon Resp Med. 2013;03(1). 10.4172/2161-105X.1000140
82. Wellinghausen N Straube E Freidank H: Low prevalence of Chlamydia pneumoniae in adults with community-acquired pneumonia. Int J Med Microbiol. 2006;296(7):485-91. 16890487 10.1016/j.ijmm.2006.05.003
83. Guo D Cai Y Chai D: The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65(9):631-40. 21038838
84. Svanström H Pasternak B Hviid A: Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ. 2014;349:g4930. 25139799 10.1136/bmj.g4930 4138354
85. Ray WA Murray KT Hall K: Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012;366(20):1881-90. 22591294 10.1056/NEJMoa1003833 3374857 F1000 Recommendation
86. Schembri S Williamson PA Short PM: Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ. 2013;346:f1235. 23525864 10.1136/bmj.f1235
87. Mortensen EM Halm EA Pugh MJ: Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311(21):2199-208. 24893087 10.1001/jama.2014.4304 4109266
88. Nie W Li B Xiu Q: β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(6):1441-6. 24535276 10.1093/jac/dku033
89. Postma DF van Werkhoven CH van Elden LJ: Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312-23. 25830421 10.1056/NEJMoa1406330 F1000 Recommendation
90. Garin N Genné D Carballo S: β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894-901. 25286173 10.1001/jamainternmed.2014.4887 F1000 Recommendation
91. Schouten JA Prins JM Bonten MJ: Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med. 2005;63(8):323-35. 16186645
92. Burkhardt O Ewig S Haagen U: Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J. 2010;36(3):601-7. 20185423 10.1183/09031936.00163309
93. Schuetz P Briel M Christ-Crain M: Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55(5):651-62. 22573847 10.1093/cid/cis464 3412690 F1000 Recommendation
94. Cooke J Butler C Hopstaken R: Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI). BMJ Open Respir Res. 2015;2(1):e000086. 25973210 10.1136/bmjresp-2015-000086 4426285
95. Little P Stuart B Moore M: Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial. Lancet Infect Dis. 2013;13(2):123-9. 23265995 10.1016/S1473-3099(12)70300-6 F1000 Recommendation
96. Murray C Shaw A Lloyd M: A multidisciplinary intervention to reduce antibiotic duration in lower respiratory tract infections. J Antimicrob Chemother. 2014;69(2):515-8. 24022067 10.1093/jac/dkt362
97. DiazGranados CA Dunning AJ Kimmel M: Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635-45. 25119609 10.1056/NEJMoa1315727
98. Pletz MW Welte T: Pneumococcal and influenza vaccination. In: Chalmers JD, Pletz MW, Aliberti S, editors. Community-Acquired Pneumonia. European Respiratory Society,2014;266-284. Reference Source
99. Crépey P de Boer PT Postma MJ: Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza Other Respir Viruses. 2015;9(Suppl 1):39-46. 26256294 10.1111/irv.12318 4549101
100. Moberley S Holden J Tatham DP: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1:CD000422. 23440780 10.1002/14651858.CD000422.pub3 F1000 Recommendation
101. Maruyama T Taguchi O Niederman MS: Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomised and placebo controlled trial. BMJ. 2010;340:c1004. 20211953 10.1136/bmj.c1004 2834887
102. Schiffner-Rohe J Witt A Hemmerling J: Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk - A Systematic Review and Meta-Analysis. PLoS One. 2016;11(1):e0146338. 26761816 10.1371/journal.pone.0146338 4711910 F1000 Recommendation
103. Bonten MJ Huijts SM Bolkenbaas M: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. 25785969 10.1056/NEJMoa1408544 F1000 Recommendation
104. Galanis I Lindstrand A Darenberg J: Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(3): pii: ERJ-01451-2015. 26797033 10.1183/13993003.01451-2015
105. Richter SS Diekema DJ Heilmann KP: Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother. 2014;58(11):6484-9. 25136018 10.1128/AAC.03344-14 4249410 F1000 Recommendation
106. van der Linden M Falkenhorst G Perniciaro S: Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS One. 2015;10(7):e0131494. 26132078 10.1371/journal.pone.0131494 4488910